Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases

Liver International

Volumn 26, Issue 9, 2006, Pages 1087-1094

  Liu, Chen Hua ^a   Lin, Jou Wei ^a   Tsai, Feng Chiao ^a   Yang, Pei Ming ^a   Lai, Ming Yang ^a   Chen, Jun Herng ^a   Kao, Jia Horng ^a   Chen, Ding Shinn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis C; Duplex Doppler ultrasonography; Hepatic fibrosis; Noninvasive test; Persistent normal alanine aminotransferase; Splenic arterial pulsatility index

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTERY RESISTANCE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; FEMALE; HEPATIC ARTERY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PORTAL VEIN; PREDICTION; PULSE WAVE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPLEEN ARTERY; VIRUS CARRIER;

ADULT; AGING; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CARRIER STATE; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PULSE; SENSITIVITY AND SPECIFICITY; SPLENIC ARTERY; ULTRASONOGRAPHY; ULTRASONOGRAPHY, DOPPLER;

EID: 33749592154     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01355.x     Document Type: Article

References (46)

1. Lauer G M, Walker B D. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Bacon B R. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36: S179-84.
3. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, consensus statement. European Association for the study of the liver. J Hepatol 1999; 30: 956-61.
4. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: Patients with normal aminotransferase levels. Hepatology 1997; 26: S133-6.
5. Puoti C, Guido M, Mangia A, Persico M, Prati D. Committee on HCV carriers with normal alanine aminotransferase levels of the Italian Association for the Study of the Liver. Clinical management of HCV carriers with normal aminotransferase levels. Digest Liver Dis 2003; 35: 362-9.
6. Gholson C F, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels: A clinical histologic study. Am J Gastroenterol 1997; 92: 1788-92.
7. Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-8.
8. Conry-Cantilena C, Vanraden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-6.
9. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. Hepatology 2002; 36: 973-7.
10. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4.
11. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760-4.
12. Martinot-Peignoux M, Boyer N, Cazal-Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 1000-5.
13. Mathurin P, Moussali J, Cadranel J F, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.
14. Jamal M M, Soni A, Quinn P G, Wheeler D E, Arora S, Johnston D E. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30: 1307-11.
15. Okanoue T, Makiyama A, Nakayama M, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005; 43: 599-605.
16. Hui C K, Belaye T, Montegrande K, Wright T L. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38: 511-7.
17. Zeuzem S, Diago M, Gane E, et al. PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
18. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.
19. Cadranel J F, Rufat P, Degos F. Practice of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
20. Mcgill D B, Rakela J, Zinsmeister A R, Ott B J. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-400.
21. Maharaj B, Maharaj R J, Leary W P, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5.
22. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
23. Colleredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
24. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-24.
25. Imbert-Bismut F, Ratziu V, Multivirc Group. et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-75.
26. Poyanrd T, Bedossa P. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR cooperative study groups. J Viral Hepatol 1997; 4: 199-208.
27. Wai C T, Greeson J K, Fontana R J, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
28. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
29. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-45.
30. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-93.
31. Fabris C, Smirne C, Toniutto P, et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: The role of AST to the platelet ratio index. Clin Biochem 2006; 39: 339-43.
32. Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27: 979-85.
33. Koda M, Murawaki Y, Kawasaki H, Ikawa S. Portal blood velocity and portal blood flow in patients with chronic viral hepatitis: Relation to histological liver fibrosis. Hepatogastroenterology 1996; 43: 199-202.
34. Sacerdoti D, Merkel C, Bolognesi M, Amodio P, Angeli P, Gatta A. Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis; relationship with portal hemodynamics. Gastroenterology 1995; 108: 1152-8.
35. Schneider A W, Kalk J F, Klein C P. Hepatic arterial pulsatility index in cirrhosis: Correlation with portal pressure. J Hepatol 1999; 30: 876-81.
36. Bolongnesi M, Sacerdoti D, Merkel C, et al. Splenic Doppler impedance indices: Influence of different portal hemodynamic conditions. Hepatology 1996; 23: 1035-40.
37. Bolognesi M, Sacerdoti D, Merkel C, Bombonato G, Gatta A. Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color Doppler. Ultrasound Med Biol 2001; 27: 901-7.
38. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
39. Hanley J A, Mcneil B J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
40. Lin D Y, Sheen I S, Chiu C T, Lin S M, Kuo Y C, Liaw Y F. Ultrasonographic changes of early cirrhosis in chronic hepatitis B: A longitudinal study. J Clin Ultrasound 1993; 21: 303-8.
41. Le Calvez S, Thabut D, Messous D, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004; 39: 862-3.
42. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.
43. Giannini E, Testa R. Noninvasive diagnosis of fibrosis: The truth is rarely pure and never simple. Hepatology 2003; 38: 1312-3.
44. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
45. Wong J B, Koff R S. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000; 133: 665-75.
46. Sacerdoti D, Gaiani S, Buonamico P, et al. Interobserver and interequipment variability of hepatic, splenic, and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. J Hepatol 1997; 27: 986-92.